CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

ClevudineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug382 Duodenal biopsy Wiki 1.00
drug1008 Saliva Wiki 1.00
drug505 Hydroxychloroquine Wiki 0.11

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D017250 Caliciviridae Infections NIH 1.00
D003141 Communicable Diseases NIH 0.11
D007239 Infection NIH 0.07

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 The Randomized, Open, Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg once a day for 14 days (maximum up to 21 days) and of Hydroxychloroquine 200mg twice a day for 14 days (maximum up to 21 days) of administration in patients with moderate COVID-19.

NCT04347915 COVID-19 Drug: Clevudine Drug: Hydroxychloroquine

Primary Outcomes

Description: The primary efficacy endpoint for this clinical trial is the rate of patients with negative SARS-Coronavirus-2 (SARS-CoV-2) in a two-day continuous Real-Time-RT-PCR test from baseline to before the 15th day.

Measure: The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)

Time: within 15days

Secondary Outcomes

Measure: The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests

Time: 4th, 8th, 15th, and 22nd day after the baseline

Measure: The rate of subjects indicated by the improvement of lung invasive

Time: within 29days

Measure: The change of viral load

Time: 4th, 8th, 15th, 22nd, and 29th day after the baseline

No related HPO nodes (Using clinical trials)